FIRECREST Customer Support

Critical care trials face variability from heterogeneous disease, complex endpoints, and rapid clinical change, increasing operational risk. A more strategic, experience-led approach can strengthen feasibility, site sele...

Join ICON Biotech at CTO East Coast 2026, taking place 30 June – 1 July at the Boston Marriott Burlington, MA. Meet our team at Booth \#18 to learn how our specialised clinical development services support biotech progra...

Oligonucleotide (ON) drug development is accelerating rapidly—but first‑in‑human (FIH) studies remain complex. Listen to our recent webinar where specialists discussed: - Translational PK/PD and toxicity considerations ...

ICON reports first quarter 2026 results. Quarter one revenue of $2,034.0 million. Net business wins in the quarter of $2,880 million; a net book-to-bill of 1.42. Read more https://ow.ly/rfbO50Zg1vj

Recent regulatory shifts have critical implications for how biosimilar developers generate and prioritise information. Read ICON’s latest article in PharmTech Magazine, to learn what these changes mean for data collect...

ICON will be attending #SCDMChina, taking place from 3 - 4 July in Shanghai, China. Stop by booth \#6 to connect with our team and discover how ICON is transforming clinical research with innovative, data-driven solutio...

ICON has selected Microsoft as a preferred technology partner to power AI-enabled clinical development. This partnership incorporates an enterprise-wide deployment of Microsoft 365 Copilot along with an enterprise-grade ...

Osivelotor is an oral investigational drug for the treatment of sickle cell disease (SCD) designed to inhibit hemoglobin polymerization. In a phase 1, open-label ADME study conducted in healthy participants at ICON’s cli...

Cut point determination is essential in ADA assay development, and while statistical methods like Tukey’s test can lead to ultra-low cut points (ULCPs), concerns around reliability and false positives may be overstated. ...

ICON Biotech will be onsite at CTO East Coast, taking place 30 June – 1 July at the Boston Marriott Burlington, MA. As a leading provider of integrated clinical research services, ICON supports oncology and biotech compa...

We are excited to announce that Cytek Aurora 5L Spectral Flow Cytometers are now live in our bioanalytical labs in the Netherlands and US. With the new addition we are offering: 1) Development/transfer, validation, and ...

Modern biologics manufacturing demands regulatory strategies that keep pace with evolving modalities, data driven controls and continuous processing. This article outlines practical considerations for aligning viral saf...